Azacitidine (NCT06504459)

Name: Azacitidine trial for Acute Monocytic Leukemia (NCT06504459)
Uploaded: 2026-10-31T22:33:38.588Z
Duration: 1 min 23 s
Description: Azacitidine trial for Acute Monocytic Leukemia (NCT06504459). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06504459.

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML: a one-minute explainerNCT065044591 min

Azacitidine trial for Acute Monocytic Leukemia (NCT06504459). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed monocytic AML, or AML with N/KRAS, FLT3, NF1, PTPN11 or CBL mutations, who cannot receive or decline intensive induction chemotherapy.

The idea: venetoclax blocks BCL-2, a protein that helps cancer cells survive. It joins cladribine and cytarabine initially. Responders then alternate that combination with azacitidine plus venetoclax. Marrow biopsies assess response. Researchers measure complete-remission rates, including remissions with incomplete blood-count recovery.

This phase 2 study plans 40 patients. Curtis Lachowiez leads it at OHSU; Miami and Portland are the two recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.